美罗培南治疗儿童急性白血病化疗期间合并院内感染的临床分析

目的评价美罗培南治疗儿童急性白血病化疗期间中性粒细胞减少合并院内感染时的临床疗效及安全性。方法52例儿童急性白血病患者强化疗后骨髓抑制期合并院内感染,开始感染时即使用美罗培南28例,在其他广谱抗生素无效的情况下改用美罗培南24例,美罗培南用法每次20mg/kg,每8小时1次,评价治疗效果及不良反应。结果美罗培南在治疗儿童急性白血病中性粒细胞减少合并院内感染的有效率为82.7%（43/52）,且副作用少。开始使用美罗培南组起效时间明显低于更换使用美罗培南组（P〈0.05）,且使用抗生素的时间在开始即使用美罗培南组明显少于更换使用美罗培南组（P〈0.05）。两组的治疗效果差异无显著性。结论美罗培南治疗儿童急性白血病患者化疗后骨髓抑制期合并感染效果明显且较安全,可作为儿童急性白血病患者化疗后骨髓抑制期合并感染的首选药物之一。     

重症肺炎新生儿支气管肺泡灌洗液 病原菌分布及耐药性

目的研究重症肺炎新生儿支气管肺泡灌洗液的病原菌分布和耐药性。方法选择2016年4月至2018年4月在本院呼吸科治疗的新生儿268例,其中符合重症肺炎诊断标准的患儿142例,归为重症肺炎组;不符合重症肺炎诊断标准的患儿126例,归为对照组。检测患儿肺泡灌洗液病原菌分布情况和耐药情况。结果重症肺炎组患儿肺炎克雷伯菌、流感嗜血菌、铜绿假单胞菌、阴沟肠杆菌、大肠埃希菌、金黄葡萄球菌、溶血葡萄球菌、表皮葡萄球菌、肺炎链球菌、草绿链球菌检出率明显高于对照组。肺炎克雷伯菌对亚胺培南,美罗培南的耐药性为0.0%,大肠埃希菌对亚胺培南,美罗培南,阿米卡星的耐药性为0.0%,阴沟肠杆菌对亚胺培南,美罗培南,左氧氟沙星的耐药性为0.0%,肺炎链球菌对万古霉素的耐药性为0.0%,金黄葡萄球菌对万古霉素的耐药性为0.0%。结论新生儿重症肺炎患者病原菌以革兰阴性菌为主,亚胺培南、美罗培南、万古霉素可以用于治疗新生儿重症肺炎,但由于其毒副作用较大,应严格把握适应症。     

某院感染科病房住院患者常见病原菌分布及 耐药性分析

目的对感染科病房住院患者临床常见病原菌的分布及其耐药性进行分析,为临床预防和治疗感染性疾病提供依据。方法回顾性分析中国医科大学附属第一医院感染科病房2012年1月至2016年12月从住院患者体液及组织样本中分离的病原菌,对其耐药情况进行分析。结果 5年中感染科共分离出非重复病原菌1 266株,其中革兰阴性菌786株,占62.09%,分离率居前3位的是大肠埃希菌、肺炎克雷伯菌以及铜绿假单胞菌,分别占17.22%、15.24%和10.58%;革兰阳性菌共480株,占37.91%,分离率居前3位的是屎肠球菌、草绿色链球菌以及金黄色葡萄球菌,分别占9.79%、7.50%和6.00%。产超广谱β-内酰胺酶(ESBLs)大肠埃希菌和肺炎克雷伯菌检出率分别为66.7%和28.8%。大肠埃希菌对亚胺培南和美罗培南的耐药率分别为0.95%和3.79%,肺炎克雷伯菌对亚胺培南和美罗培南的耐药率分别为2.80%和2.80%。结论我院感染科病房住院患者感染病原菌以革兰阴性菌为主,为有效地控制和避免耐药菌感染的发生,临床应根据药敏试验结果合理应用抗菌药物。     

Development of an HPLC method for the determination of doripenem in human and mouse serum

A HPLC method utilizing solid phase extraction was developed to analyze doripenem (formerly S-4661) in human and mouse serum. A reversed-phase column was used with a UV detector set at 295 nm. The mobile phase consisted of methanol and phosphate buffer at a flow rate of 1.5 ml/min. Meropenem was used as the internal standard. The standard curve was linear over a range of 0.5-40 microg/ml. The assay is simple, reproducible, and accurate and has been used successfully to analyze doripenem concentrations from a murine pharmacokinetic study.     

Efficacy of meropenem in the treatment of severe complicated urinary tract infections]

The clinical and bacteriological efficacies of meropenem in the treatment of 12 patients with urinary tract infection were studied. In 8 patients the drug was administered intravenously in a dose of 1 g every 8 hours and in 4 patients with the creatinine clearance below 50 ml/min it was administered in a dose of 1 g every 12 hours (the treatment course of 7 to 10 days). Meropenem was used in the monotherapy. Severe complicated urinary tract infections were mainly observed in the patients with long-term urolithiasis, subjected to repeated surgical interventions and isolating as a rule polyresistant strains of Pseudomonas aeruginosa and E.agglomerans as the pyelonephritis pathogens at a titre of 5 x 10(5)-5 x 10(8) microbial cells per 1 ml of the urine susceptible to meropenem in 80 to 96 per cent of the cases. The clinical efficacy of the drug was stated in all the patients while the bacteriological efficacy amounted to 88.9 per cent.     

Interaction and photo–induced cleavage studies of meropenem drug with human serum albumin using spectroscopic and molecular docking investigations

The interaction between Meropenem drug and human serum albumin (HSA) has been studied under physiological condition in Tris–HCl buffer solution at pH 7.4 by various spectroscopic (UV spectra, fluorescence spectra, CD spectra), Photo–induced HSA cleavage, and molecular docking techniques. The results of fluorescence titration revealed that the Meropenem strongly quench the intrinsic fluorescence of HSA through a static quenching procedure. Binding constants (K_b) and the number of binding sites (n ? 1) were calculated using modified Stern–Volmer equations. The thermodynamic parameters ΔG, ΔH and ΔS at different temperatures were calculated which revealed that the electrostatic and hydrogen bonding interactions play a major role in HSA–Meropenem association. The distance r between donor (HSA) and acceptor (Meropenem) was obtained according to fluorescence resonance energy transfer (FRET) and the alterations of HSA secondary structure induced by Meropenem were confirmed by FT–IR and CD measurements. The molecular docking technique was utilized to ascertain the mechanism and mode of action towards the molecular target HSA indicating that Meropenem was located within the subdomain IIA of protein by electrostatic interactions and hydrogen bonds, consistent with the corresponding experimental results. Additionally, Meropenem shows efficient photo–induced HSA cleavage. Our results may provide valuable information to understand the mechanistic pathway of drug delivery and to pharmacological behavior of drug.

• Research Highlights

• The interaction of Meropenem with HSA was studied by spectroscopic, photo-induced cleavage and molecular docking techniques.

• The secondary structure of protein has been changed upon the interaction with Meropenem.

• Subdomain IIA of the HSA is found to be the main binding site for Meropenem.

Communicated by Ramaswamy H. Sarma     

Synergistic effects of zinc oxide nanoparticles and various antibiotics combination against Pseudomonas aeruginosa clinically isolated bacterial strains

P. aeruginosa causes mostly both community-acquired and nosocomial infections, which leads to serious therapeutic challenges for treatment and requirement of appropriate therapeutic agent is needed which can combat antibiotic resistance. The research work was performed to investigate the effect of Zinc Oxide nanoparticles (ZnO NPs) in combination with Meropenem, Ciprofloxacin, and Colistin against clinical isolated strains of P. aeruginosa and ATCC 27853 strain.The minimum inhibitory concentration (MIC) of ZnO NPs and the antibiotics (Meropenem, Ciprofloxacin, and Colistin), was determined by the microdilution method and the results of MIC values were ranging between 1 and 16 µg/mL was found to be shown for antibiotics and ZnO NPs found to showed highest MIC values ranging from 2000 to 4000 µg/mL. The fractional inhibitory concentration index (FICI) was calculated using checkerboard method to test the combinations of ZnO NPs and the antibiotics (Meropenem, Ciprofloxacin, and Colistin), and among all the six P. aeruginosa clinical isolated strains P. aeruginosa (MRO-16-3 and MRO-16-4), showed FICI as 0.24 and 0.39 9, whereas P. aeruginosa ATCC 27853 strain showed FICI as 0.41 which indicates synergistic effect with Colistin.The time kill growth curve showed synergistic effect for the combination of Colistin and ZnO NPs against P. aeruginosa (MRO-16-3 and MRO-16-) strains. P. aeruginosa (MRO-16-3) was found to be highly sensitive to Colistin with an MIC of 2 µg/mL, which has shown to reduced bacterial growth to zero colonies after 24 h of incubation.In conclusion, combination of Colistin and ZnO NPs at appropriate dosage intervals might be beneficial as using therapeutic agent in treatment of P. aeruginosa ailments.     

婴儿泌尿道感染的病原菌分布及耐药性分析

目的探讨婴儿泌尿道感染的病原菌构成及其耐药情况,以指导临床合理用药。方法对2012年5月至2013年7月某院门诊及住院婴儿送检的尿标本进行分离培养,用全自动微生物鉴定／药敏系统进行菌种鉴定和药敏试验,同时对大肠埃希菌和肺炎克雷伯菌进行超广谱β-内酰胺酶检测。结果婴儿泌尿道感染以大肠埃希菌检出率最高（46．24％）,其余依次是粪肠球菌（22．04％）、肺炎克雷伯菌（7．80％）、屎肠球菌（5．37％）、铜绿假单胞菌（4．30％）。大肠埃希菌和肺炎克雷伯菌超广谱β-内酰胺酶检出率分别为46．51％和58．62％。革兰阴性菌对亚胺培南、美罗培南的耐药率为0,对氨苄西林耐药率最高（〉80％）。革兰阳性菌对万古霉素耐药率为0,对苯唑西林、妥布霉素的耐药率100％。结论婴儿泌尿道感染病原菌以大肠埃希菌为主;大肠埃希菌、肺炎克雷伯菌超广谱β-内酰胺酶检出率高,应引起重视;临床医师要根据药敏结果指导用药,对危重病例和存在泌尿道畸形反复发作病例,革兰阴性菌可选用亚胺培南、美罗培南,革兰阳性菌可选用万古霉素。     

个体化美罗培南治疗铜绿假单胞菌感染老年患者的临床经验

目的:探讨个体化美罗培南对感染铜绿假单胞菌老年患者的有效性及安全性。方法:110例经细菌培养已证实铜绿假单胞菌感染的老年肺部感染患者,随机分成两组,美罗培南常规剂量组和公式定量法剂量组(个体化组),分析两组美罗培南的疗效及安全性。结果:个体化剂量组的美罗培南平均用药0.8 g/12 h较常规剂量组的1.0 g/12 h低。个体化剂量组的有效率为78.2%高于常规剂量组的63.6%,但两组差异无显著性(P>0.05)。轻度不良反应的发生率个体化剂量组高(P<0.05),两组未发生肝功能异常病例,常规剂量美罗培南对肾功能有一定影响,而个体化用药能减轻美罗培南对肾功能的影响。结论:美罗培南个体化给药治疗铜绿假单胞菌感染的老年肺部感染患者可以在保证疗效的前提下提高安全性,减少对肾功能的影响。     

Efficacy of some new antibiotics in treating experimental brucellosis]

Brucella pathogens are highly susceptible in vitro to pefloxacin, lomefloxacin, meropenem and azithromycin. High efficacy of these drugs was demonstrated for experimental brucellosis treatment, azithromycin being the most active. Meropenem and azithromycin implementation resulted in more rapid and full normalization of the bactericidial and energy systems of the experimental animals peripheral blood cells.     

Determination of synergistic effects of antibiotics and Zno NPs against isolated E. Coli and A. Baumannii bacterial strains from clinical samples

The mortality rates has been increased globally due to multidrug resistant (MDR) E.coli and A.baumanii bacterial strains and also there is an emerging resistance of the Enterobacteriaceae family of bacteria to Carbapenem antibiotics (CRE) in Saudi Arabia. The main aim of our research study is to isolate E.coli and A. baumannii bacterial species from various collected clinical samples and to evaluate the MIC and FICI of Colistin, Ciprofloxacin, Meropenem and ZnO NPs and in combination of Colistin, Ciprofloxacin, Meropenem with ZnO NPs.The clinical isolated strains of A. baumannii (MRO-17-13) and A. baumannii (MRO-17–25) was found to be sensitive towards colistin with 0.5 μg/mL concentration, whereas, all the isolated A. baumannii strains showed similar MIC value 2 mg/mL when tested with ZnO NPs, the MIC value for the ZnO NPs was found to be similar for all the E.coli strains 0.25 mg/mL. The effects of all Ciprofloxacin concentrations used in the study were bacteriostatic against E. coli (01UR19006568-01) strain but 1 mg/mL concentration of ZnO NPs alone is showed bactericidal activity, ZnO NPs effect was found to be concentration dependent, as highest concentration of ZnO NPs showed strongest antibacterial effect. In conclusion, more investigation is required to evaluate the acceptable concentration of Zno NPs and antibiotics selected to avoid toxicity and must be tested against more clinically isolated gram-negative bacterial strains.     

四川绵阳地区肺炎链球菌流行病学特征

目的了解四川绵阳地区肺炎链球菌的耐药情况,为临床合理用药及感染控制提供依据。方法收集我院2015年1月至2017年12月临床分离的718株肺炎链球菌,并对其药物敏感性检测结果进行分析。结果肺炎链球菌对红霉素和四环素的耐药率最高,均在95%以上;对左氧氟沙星、莫西沙星、泰利霉素、氯霉素的敏感性较高,均在89%以上;对青霉素、美罗培南、阿莫西林和头孢类抗生素的耐药率均在30%以上;未检出万古霉素和利奈唑胺耐药株。肺炎链球菌主要耐药模式为头孢曲松+红霉素+四环素+复方新诺明+美罗培南+青霉素+阿莫西林+头孢噻肟,占19.44%。2017年肺炎链球菌青霉素敏感株和不敏感菌株对美罗培南、阿莫西林、厄他培南、头孢噻肟、头孢曲松、氧氟沙星、复方新诺明和氯霉素的不敏感率比较差异有统计学意义(P0.05)。结论本地区肺炎链球菌对红霉素、四环素耐药率较高,不适用于肺炎链球菌感染的治疗;对青霉素、美罗培南、阿莫西林和头孢类抗生素不敏感率较高,应慎重用于经验治疗;对万古霉素、利奈唑胺和喹诺酮类药物敏感性较高,临床可合理使用。     

美罗培南对1139株革兰阴性杆菌抗菌活性研究

目的分析美罗培南对革兰阴性杆菌的抗菌活性,为临床合理使用美罗培南提供正确依据。方法将宁波市第一医院2004年6月至2005年8月的临床各种标本分离获得的革兰阴性杆菌在VITEK-32微生物自动鉴定分析仪中进行鉴定和药敏试验。用双纸片法及2-巯基丙酸抑制试验进行ESBLs、AmpC和金属酶的检测。结果共检出临床常见的革兰阴性杆菌1139株,其中肠杆菌科559株（大肠埃希菌309株,肺炎克雷伯菌186株,阴沟肠杆菌64株）,非发酵菌580株（铜绿假单胞菌227株,嗜麦芽窄食单胞菌72株,脑膜脓毒黄杆菌44株．鲍曼不动杆菌178株．洋葱伯克霍尔德菌30株,荧光假单胞菌29株）。美罗培南对大肠埃希菌、肺炎克雷伯菌、阴沟肠杆菌、铜绿假单胞菌、鲍曼不动杆菌、嗜麦芽窄食单胞菌、脑膜脓毒黄杆菌、荧光假单胞菌的耐药率分别为0．0％、0．0％、0．0％、22．9％、23．6％、90．3％、100．0、63．3％和3．4％。结论美罗培南对革兰阴性杆菌有很强的抗菌活性,其抗菌活性要强于亚胺培南,是目前治疗肠杆菌科细菌特别是产ESBLs、AmpC酶细菌感染的危重患者的最理想用药。美罗培南耐药率呈逐年增加趋势,应引起重视。美罗培南对嗜麦芽窄食单胞菌、脑膜脓毒黄杆菌、洋葱伯克霍尔德菌活性很低,临床对于上述细菌感染不应选用美罗培南。     

Antibiotic therapy of cystic fibrosis in children]

It is postulated that P. aeruginosa in monoculture or in association with Staphylococcus aureus keeps its leading position in chronic bacterial inflammatory broncho-pulmonary processes in children with cystic fibrosis. Antibiotic resistant strains of Burkholderia cepacia, Stenotrophomonas maltophila, Alcaligenes xylosoxidans were revealed (7.1% of the strains). P. aeruginosa strains were susceptible to aminoglycosides, ciprofloxacin, and polymixin B. Susceptibility of smooth and mucoid forms of P. aeruginosa to ceftazidime stayed at the level of 49.6-57.1%. Such microbial associations as P. aeruginosa sm. + S. aureus, P. aeruginosa sm. + P. aeruginosa muc. + S. aureus were mainly susceptible to ciprofloxacin, aminoglycosides and resistant to ceftasidime. Meropenem, cefepim and ciprofloxacin are highly effective antibiotics for the treatment of broncho-pulmonary processes exacerbations at children with chronic P. aeruginosa cystic fibrosis. Intravenous use of antibiotics out of hospital for the treatment of the children with cystic fibrosis is clinically effective, and is economically and psychologically reasonable. It should be used more widely in medical practice.     

洋葱伯克霍尔德菌致恶性肿瘤患者医院获得性感染的耐药性分析

目的分析我院恶性肿瘤患者医院获得性感染洋葱伯克霍尔德菌的临床特点及对常用抗菌药物的耐药性,为临床合理治疗提供依据。方法回顾性分析2011年1月至2013年12月,从我院恶性肿瘤感染患者送检的细菌培养标本;细菌鉴定用美国BD公司phoenix-100全自动细菌鉴定药敏系统,药敏试验采用纸片法,同时使用WHONET 5.6软件对相关资料进行统计。结果从检测部位分析主要分布在下呼吸道（74.1%）,其次为血液（9.4%）;药敏试验表明139株洋葱伯克霍尔德菌对米诺环素、氯霉素、美罗培南、头孢他啶和头孢哌酮/舒巴坦仍较敏感,可作为临床治疗洋葱伯克霍尔德菌感染的首选药物,其余15种抗菌药物的耐药率高达30.0%~100%。结论洋葱伯克霍尔德菌在恶性肿瘤患者中的耐药现象非常严重,临床应引起高度关注,及早进行微生物学检测,并根据药敏试验结果合理选用抗菌药物。     

Insights from modeling the 3D structure of New Delhi metallo-β-lactamse and its binding interactions with antibiotic drugs

New Delhi metallo-beta-lactamase (NDM-1) is an enzyme that makes bacteria resistant to a broad range of beta-lactam antibiotic drugs. This is because it can inactivate most beta-lactam antibiotic drugs by hydrolyzing them. For in-depth understanding of the hydrolysis mechanism, the three-dimensional structure of NDM-1 was developed. With such a structural frame, two enzyme-ligand complexes were derived by respectively docking Imipenem and Meropenem (two typical beta-lactam antibiotic drugs) to the NDM-1 receptor. It was revealed from the NDM-1/Imipenem complex that the antibiotic drug was hydrolyzed while sitting in a binding pocket of NDM-1 formed by nine residues. And for the case of NDM-1/Meropenem complex, the antibiotic drug was hydrolyzed in a binding pocket formed by twelve residues. All these constituent residues of the two binding pockets were explicitly defined and graphically labeled. It is anticipated that the findings reported here may provide useful insights for developing new antibiotic drugs to overcome the resistance problem.     

美罗培南联合常规治疗对脓毒症休克合并急性肾功能不全患者炎性因子、肾功能及免疫球蛋白的影响

摘要 目的：探讨脓毒症休克合并急性肾功能不全患者在常规治疗的基础上联合美罗培南治疗后对其肾功能、炎性因子及免疫球蛋白的影响。方法：选取我院80例脓毒症休克合并急性肾功能不全患者,根据随机数字表法分为对照组（n=40）和研究组（n=40）,对照组予以常规治疗,研究组在对照组的基础上联合美罗培南治疗,比较两组患者疗效、炎性因子[降钙素原（PCT）、C反应蛋白（CRP）、白介素-6（IL-6）]、肾功能[尿素氮（BUN）和血肌酐（Scr）]、免疫球蛋白[免疫球蛋白G（IgG）、免疫球蛋白M（IgM）、免疫球蛋白A（IgA）]及不良反应。结果：研究组治疗1个疗程后的临床总有效率为90.00%（36/40）,高于对照组的72.50%（29/40）（P<0.05）。两组不良反应发生率比较无差异（P>0.05）。两组患者治疗1个疗程后BUN、Scr和PCT、CRP、IL-6均下降,且研究组低于对照组（P<0.05）。两组患者治疗1个疗程后IgG、IgM均升高,且研究组高于对照组（P<0.05）;两组患者治疗1个疗程后IgA组间及组内比较无差异（P>0.05）。结论：脓毒症休克合并急性肾功能不全患者在常规治疗的基础上联合美罗培南治疗,疗效显著,可有效改善肾功能及免疫功能,减轻炎性反应,且安全性较好。     

Synthesis,pH-dependent,and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis

Meropenem, a broad-spectrum parenteral β-lactam antibiotic, in combination with clavulanate has recently shown efficacy in patients with extensively drug-resistant tuberculosis. As a result of meropenem’s short half-life and lack of oral bioavailability, the development of an oral therapy is warranted for TB treatment in underserved countries where chronic parenteral therapy is impractical. To improve the oral absorption of meropenem, several alkyloxycarbonyloxyalkyl ester prodrugs with increased lipophilicity were synthesized and their stability in physiological aqueous solutions and guinea pig as well as human plasma was evaluated. The stability of prodrugs in aqueous solution at pH 6.0 and 7.4 was significantly dependent on the ester promoiety with the major degradation product identified as the parent compound meropenem. However, in simulated gastrointestinal fluid (pH 1.2) the major degradation product identified was ring-opened meropenem with the promoiety still intact, suggesting the gastrointestinal environment may reduce the absorption of meropenem prodrugs in vivo unless administered as an enteric-coated formulation. Additionally, the stability of the most aqueous stable prodrugs in guinea pig or human plasma was short, implying a rapid release of parent meropenem.     

Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection

A simple and economical high performance liquid chromatography method was developed and validated for routine analysis of 12 Penicillin, Cephalosporin and Carbapenem antibiotics in 200 μL of human plasma. Antibiotics determined were Ceftazidime, Meropenem, Ceftriaxone, Ampicillin, Cefazolin, Ertapenem, Cephalothin, Benzylpenicillin, Flucloxacillin, Dicloxacillin, Piperacillin and Ticarcillin. There was a common sample preparation approach involving precipitation of proteins with acetonitrile and removal of lipid-soluble components by a chloroform wash. Separations were performed on a Waters X-bridge C18 column with, depending on analytes, one of three acetonitrile–phosphate buffer mobile phases. Detection was by UV at 210, 260 and 304 nm. Validation has demonstrated the method to be linear, accurate and precise. The method has been used in a pathology laboratory for therapeutic drug monitoring (TDM) of beta-lactams in critically ill patients.     

非产超广谱β-内酰胺酶肺炎克雷伯杆菌的耐药性分析

目的了解临床分离肺炎克雷伯杆菌中非产超广谱β-内酰胺酶（ESBLs）菌株对18种常见抗菌药物的耐药性。方法CLSI表型确证试验-纸片增强法检测非产ESBLs肺炎克雷伯菌,K-B法测定非产ESBLs肺炎克雷伯杆菌对18种常见抗菌药物的敏感性。结果非产ESBLs肺炎克雷伯杆菌株对头孢唑啉、头孢呋辛的耐药率〉50．0％,对其余抗生素的耐药率均低于25．0％,对亚胺培南、美罗培南非常敏感,耐药率分别为2．3％和2．0％;痰标本的分离株对头孢唑啉、头孢呋辛的耐药率明显高于血、尿液标本分离株,差异有统计学意义（P〈0．05）。结论非产ESBLs肺炎克雷伯杆菌对第一、二代头孢菌素耐药显著,对第三代头孢菌素、亚胺培南、美罗培南等抗生素比较敏感。